Jose Manuel Carrascosa Carrillo
Overview
Explore the profile of Jose Manuel Carrascosa Carrillo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
21
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hernandez Fernandez C, Borrego L, Gimenez Arnau A, Zaragoza Ninet V, Sanz Sanchez T, Miquel Miquel F, et al.
Contact Dermatitis
. 2024 Feb;
90(5):486-494.
PMID: 38348533
Background: Current frequency and features for positivity to textile dye mix (TDM) in Spain are unknown. Objectives: To study the frequency, clinical features and simultaneous positivity between TDM, para-phenylenediamine (PPD)...
2.
Maravilla-Herrera P, Merino M, Alfonso Zamora S, Balea Filgueiras J, Carrascosa Carrillo J, Delgado Sanchez O, et al.
Front Public Health
. 2023 Feb;
11:1000776.
PMID: 36778548
Introduction: Psoriasis is a chronic disease involving the skin, which significantly impacts the quality of life. Disease severity and treatment efficacy (i.e., response) are assessed through the Psoriasis Area and...
3.
Hernandez Fernandez C, Borrego L, Mercader Garcia P, Gimenez Arnau A, Sanchez Perez J, Salvador J, et al.
Contact Dermatitis
. 2022 Nov;
88(3):212-219.
PMID: 36403138
Background: Current frequency and risk factors for sensitization to methylisothiazolinone (MI), methylchloroisothiazolinone/methylisothiazolinone (MCI/MI), benzisothiazolinone (BIT) and octylisothiazolinone (OIT) in Spain are not well known. Objectives: To study the frequency of...
4.
Carrascosa Carrillo J, Baselga Torres E, Gilaberte Calzada Y, Jurgens Martinez Y, Roustan Gullon G, Yanguas Bayona J, et al.
Dermatol Ther (Heidelb)
. 2022 Apr;
12(5):1197-1210.
PMID: 35445962
Introduction: As research continues, new drugs will no doubt be added to the current pool of treatments for moderate-to-severe atopic dermatitis (AD). This raises the need for studies to determine...
5.
Zozaya N, Abdalla F, Alfonso Zamora S, Balea Filgueiras J, Carrascosa Carrillo J, Delgado Sanchez O, et al.
Expert Rev Pharmacoecon Outcomes Res
. 2022 Apr;
22(6):941-953.
PMID: 35404728
Background: Multi-criteria decision analysis (MCDA) was proposed to surmount arbitrary clinical decisions in the field of biological therapies for psoriatic patients. At the same time, MCDA may further highlight the...
6.
Zozaya N, Villoro R, Abdalla F, Alfonso Zamora S, Balea Filgueiras J, Carrascosa Carrillo J, et al.
Acta Derm Venereol
. 2022 Mar;
102:adv00678.
PMID: 35312022
Psoriasis is a chronic, systemic inflammatory disease that affects the skin, with a high impact on patients' quality of life. The aim of this study was to identify and determine...
7.
Belinchon Romero I, Dauden E, Ferrandiz Foraster C, Gonzalez-Cantero A, Carrascosa Carrillo J
Ann Med
. 2021 Oct;
53(1):1727-1736.
PMID: 34601988
Objective: To critically analyse and define therapeutic objectives, response to treatment evaluation and related decisions in psoriasis. Methods: Expert consensus meetings, a systematic and narrative reviews and a collaborative Delphi...
8.
Belinchon Romero I, Dauden E, Ferrandiz Foraster C, Gonzalez-Cantero A, Carrascosa Carrillo J
J Dermatolog Treat
. 2021 Feb;
33(3):1661-1669.
PMID: 33615959
Background: Response to treatments in psoriasis can be assessed using the PASI response 50, 75, 90 or 100. Achieving a PASI 100 response would mean a complete resolution of the...